Karyopharm Therapeutics (KPTI) Stock: Buy, Sell, or Hold?
KPTI - Karyopharm Therapeutics Inc.
$0.80
-0.06 (-7.45%)
▼
5d:
-50.48%
30d:
-55.18%
90d:
-91.66%
WAIT
LOW Confidence
Analysis Updated: Oct 2, 2026 12:00 AM ET
Earnings: Nov 02, 2026
29d
Get Alerted When KPTI Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: KPTI is down 50.5% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: KPTI is down 50.5% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: KPTI is currently trading at $0.80, which is considered oversold relative to its 30-day fair value range of $1.38 to $1.96.
Technical Outlook: Technically, KPTI is in a strong downtrend. Immediate support is located at $0.75, while resistance sits at $1.93. Short-term momentum is weak, with the stock down 7.5% recently.
Market Sentiment: KPTI scores 25/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $7.25 (+803.8%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, KPTI is in a strong downtrend. Immediate support is located at $0.75, while resistance sits at $1.93. Short-term momentum is weak, with the stock down 7.5% recently.
Market Sentiment: KPTI scores 25/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $7.25 (+803.8%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$1.38 -
$1.96
Company Quality Score
42/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
52.6%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-7.5%)
- BULLISH: Trading 803.8% below Wall St target ($7.25)
- WARNING: Composite score 42/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$1.38 -
$1.96
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$0.75
Resistance Level
$1.93
Current Trend
Strong Downtrend
Technical data as of
Oct 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-0.28
Wall Street Target
$7.25
(+803.8%)
Revenue Growth (YoY)
-11.9%
Profit Margin
-153.3%
Share & Embed Analysis
Last updated: October 03, 2026 6:57 AM ET
Data refreshes hourly during market hours. Next update: 7:57 AM
Data refreshes hourly during market hours. Next update: 7:57 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is KPTI showing a specific setup today?
Insider Activity (6 Months)
0
Buys
1
Sells
Net
INSIDERS SELLING
Recent Transactions
Reshma Rangwala
SELL
449 shares
2026-04-21
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$24 | 54 HOLD |
|
REGN
Regeneron Pharmaceutical… |
STRONG BUY
25 analysts |
$851 | 48 HOLD |
|
JAZZ
Jazz Pharmaceuticals PLC |
STRONG BUY
18 analysts |
$293 | 67 BUY |
|
MLTX
MoonLake Immunotherapeut… |
STRONG BUY
16 analysts |
$29 | 49 HOLD |
|
ACAD
ACADIA Pharmaceuticals I… |
BUY
20 analysts |
$32 | 62 BUY |
